Table 5.
Demography and comorbidities of SARS‐CoV‐2 positive children
| Study | Participants n | Median Age | Male n (%) | Comorbidities n (%) | Obesitya + n (%) | Chronic Respiratory Illness n (%) | Asthma n (%) | Immuno‐compromised/suppressedb n (%) |
|---|---|---|---|---|---|---|---|---|
| Zachariah et al. 17 (New York) | 50 | 11 | 27 (54) | 33 (67) | 11 (22) | 2 (4) | 6 (12) | 8 (16) |
| Shekerdemianet al. 51 (USA/Canada) | 48 | 13 | 25 (52) | 40 (83) | 7 (15) | 2 (4) | ‐ | 11 (23) |
| Chao et al. 75 (New York) | 46 | 13 | 31 (67) | ‐ | 14 (30) | ‐ | 11 (24) | 3 (7) |
| Godfred‐Cato et al. 69 (U.S.) | 570 | 8 | 316 (55) | ‐ | 146 (26) | 48 (8) | ‐ | ‐ |
| Kim et al. 76 (USA) | 576 | 8 | 292 (51) | 94/222 (42) | 42/111 (38) | 40/222 (18) | 30/222 (14) | 12/222 (5) |
| Leon‐Abarco 77 (Mexico) | 21,161 | ‐ | ‐ | ‐ | 655 (3) | ‐ | 806 (4) | 808 (4) |
| Ciprandi et al. 78 (Italy) | 52 | 6.2 | 24 (46) | ‐ | ‐ | ‐ | 1 (2) | ‐ |
| Garazzino et al. 16 (Italy) | 168 | 2.3 | 94 (56) | 33 (20) | ‐ | 7 (4) | ‐ | 3 (2)/4 (2) |
| Götzinger et al. 18 (Europe) | 582 | 5 | 311 (53) | 145 (25) | ‐ | 29 (5)c | 16 (3) | 3 (1)/29 (5) |
| Han et al. 4 (South Korea) | 91 | 11 | 53 (58) | 6 (7) | ‐ | 0 (0) | 3 (3) | 0 (0) |
| Swann et al. 50 (UK) | 651 | 4.6 | 367 (56) | 276 (42) | ‐ | ‐ | 45/615 (7) | 48/615 (8)/53/599 (9) |
| Yonker et al. 21 (MA, USA) | 49 | 12.7 | 23 (47) | ‐ | 13 (27) | ‐ | 6 (12) | 0 (0) |
| Antunez‐Montes et al. 22 (Latin America) | 409 | 3 | 222 (54) | 83 (20) | ‐ | ‐ | ‐ | 18 (4)/12 (3) |
Abbreviations: BMI, body mass index; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2.
Obesity is defined as BMI (or sex and weight for length percentiles for patients younger than 2) at or above the 95th percentile for age.
Solid organ transplant, hematologic malignancies, solid tumors, hematopoietic stem cell transplant recipient, aplastic anemia.
Study explicitly states or demonstrates the inclusion of asthma in data point for chronic respiratory illness.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.